drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (anti-endoglin)
drug_description
Intravenous monoclonal antibody against endoglin (CD105) on proliferating endothelial cells; anti-angiogenic via blockade of TGF-β/BMP9/10–ALK1/endoglin signaling with potential ADCC.
nci_thesaurus_concept_id
C74010
nci_thesaurus_preferred_term
Carotuximab
nci_thesaurus_definition
A human/murine chimeric monoclonal antibody directed against endoglin (CD105) with potential antiangiogenic and antineoplastic activities. Carotuximab binds to endoglin, which may result in inhibition of tumor angiogenesis and decreased tumor cell proliferation. The glycoprotein endoglin is a transforming growth factor beta-1 (TGF beta-1) accessory receptor that is highly expressed on tumor vessel endothelial cells and appears to be essential for angiogenesis.
drug_mesh_term
carotuximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric monoclonal antibody targeting endoglin (CD105) on proliferating endothelial cells; blocks TGF-β/BMP9/10–ALK1/endoglin signaling to inhibit angiogenesis and endothelial proliferation, with potential Fc-mediated ADCC, leading to anti-tumor effects via vascular targeting.
drug_name
Carotuximab
nct_id_drug_ref
NCT05401110